Docoh
Loading...

RIGL Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Company profile

Ticker
RIGL
Exchange
Website
CEO
Raul Rodriguez
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
943248524

RIGL stock data

(
)

Calendar

5 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 20.05M 20.05M 20.05M 20.05M 20.05M 20.05M
Cash burn (monthly) 3.44M 2.1M (positive/no burn) 687.08K 6.65M 5.75M
Cash used (since last report) 14.1M 8.6M n/a 2.81M 27.25M 23.57M
Cash remaining 5.95M 11.45M n/a 17.23M -7.2M -3.53M
Runway (months of cash) 1.7 5.5 n/a 25.1 -1.1 -0.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 May 21 Lyons Gary A Common Stock Grant Aquire A No No 0 25,000 0 25,000
19 May 21 Lyons Gary A Stock Option Common Stock Grant Aquire A No No 3.64 30,000 109.2K 30,000
19 May 21 Lapointe Anthony Gregg Common Stock Grant Aquire A No No 0 25,000 0 25,000
19 May 21 Lapointe Anthony Gregg Stock Option Common Stock Grant Aquire A No No 3.64 30,000 109.2K 30,000
19 May 21 Katkin Keith Common Stock Grant Aquire A No No 0 25,000 0 25,000
19 May 21 Katkin Keith Stock Option Common Stock Grant Aquire A No No 3.64 30,000 109.2K 30,000
19 May 21 Kotzin Brian L. Common Stock Grant Aquire A No No 0 25,000 0 25,000
19 May 21 Kotzin Brian L. Stock Option Common Stock Grant Aquire A No No 3.64 30,000 109.2K 30,000
19 May 21 Wasman Jane Common Stock Grant Aquire A No No 0 25,000 0 25,000
19 May 21 Wasman Jane Stock Option Common Stock Grant Aquire A No No 3.64 30,000 109.2K 30,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

85.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 153 150 +2.0%
Opened positions 27 24 +12.5%
Closed positions 24 15 +60.0%
Increased positions 40 42 -4.8%
Reduced positions 56 52 +7.7%
13F shares
Current Prev Q Change
Total value 631.39M 1.07B -40.7%
Total shares 145.17M 140.57M +3.3%
Total puts 535.1K 483.1K +10.8%
Total calls 512.1K 613.7K -16.6%
Total put/call ratio 1.0 0.8 +32.7%
Largest owners
Shares Value Change
FMR 25.51M $87.23M +22.0%
BLK Blackrock 17.6M $60.2M +0.6%
STT State Street 12.52M $42.81M +33.7%
Vanguard 8.96M $30.63M -2.1%
Tamarack Advisers 8.35M $28.56M +12.1%
Wellington Management 6.21M $21.24M -44.5%
IVZ Invesco 5.14M $17.58M +0.3%
Lord, Abbett & Co. 4.86M $16.61M NEW
Rock Springs Capital Management 4.74M $16.22M -0.0%
Millennium Management 3.68M $12.58M +257.7%
Largest transactions
Shares Bought/sold Change
Wellington Management 6.21M -4.99M -44.5%
Lord, Abbett & Co. 4.86M +4.86M NEW
FMR 25.51M +4.59M +22.0%
MS Morgan Stanley 1.38M -3.84M -73.5%
STT State Street 12.52M +3.15M +33.7%
Citadel Advisors 3.3M -3.04M -48.0%
Millennium Management 3.68M +2.65M +257.7%
Nuveen Asset Management 3.3M +2.54M +334.3%
Two Sigma Advisers 2.37M +2.01M +559.1%
Renaissance Technologies 220.5K -1.87M -89.4%

Financial report summary

?
Management Discussion
  • Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • This discussion and analysis should be read in conjunction with our financial statements and the accompanying notes included in this report and the audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2020. Our financial results for the three months ended March 31, 2021 are not necessarily indicative of results that may occur in future interim periods or for the full fiscal year.
  • This Quarterly Report on Form 10-Q contains statements indicating expectations about future performance and other forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, that involve risks and uncertainties. We usually use words such as “may,” “will,” “would,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” or the negative of these terms or similar expressions to identify these forward-looking statements. These statements appear throughout this Quarterly Report on Form 10-Q and are statements regarding our current expectation, belief or intent, primarily with respect to our operations and related industry developments. Examples of these statements include, but are not limited to, statements regarding the following: our expectations regarding the impact of the global COVID-19 pandemic; our business and scientific strategies; risks and uncertainties associated with the commercialization and marketing of TAVALISSE; in the U.S. and in Europe; risks that the FDA, EMA or other regulatory authorities may make adverse decisions regarding fostamatinib; the progress of our and our collaborators’ product development programs, including clinical testing, and the timing of results thereof; our corporate collaborations and revenues that may be received from our collaborations and the timing of those potential payments; our expectations with respect to regulatory submissions and approvals; our drug discovery technologies; our research and development expenses; protection of our intellectual property; sufficiency of our cash and capital resources and the need for additional capital; and our operations and legal risks. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including as a result of the risks and uncertainties discussed under the heading “Risk Factors” in Item 1A of Part II of this Quarterly Report on Form 10-Q. Any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: absent, accelerating, activist, adequacy, advocating, aimed, Antitrust, antiviral, assumption, attained, Biden, border, Brazil, breakdown, Britain, Chemical, cITP, CJEU, clarification, CNS, Commissioner, committee, conflicting, Consortium, constitutionality, conventional, cooperation, COVID, CPRA, CRP, deceased, deny, Digital, diverge, divergent, DOD, donor, draft, Electronic, Eli, England, ESG, ESPP, EUA, Exit, fast, faster, Ferritin, Fibrinogen, fined, fixed, fundamentally, Great, harbor, Heart, hereof, HHS, HS, HSR, hybrid, hypoxia, IAS, ICU, idiopathic, implicate, India, Internationally, intraperiod, introduced, intubated, IP, Ireland, Labor, Lily, marketplace, maximum, member, MHRA, misuse, month, mortality, nationwide, NHLBI, NIH, nineteen, Northern, Nuclear, opt, ordinal, overturning, palmoplantar, parallel, partly, penetrant, permanent, perspective, pertained, plasma, PPP, presidential, priority, professional, pronouncement, proxy, purpura, pursuit, qualification, Rain, randomised, readout, reciprocal, reclassified, reconsider, reexamining, remdesivir, resurgence, revoke, revoked, Scotland, Scottish, seventeen, Shareholder, shop, Simplifying, simply, supervisory, suppurativa, Supreme, surge, theft, tie, timeframe, topline, traditional, UKRI, unapproved, undelivered, unnecessary, unvaried, ventilation, ventilator, virtue, vivo, wAIHA, waiver, withdrew, Zealand
Removed: accident, Aid, analyzing, attack, calculated, calendar, carryback, centralized, circumvent, clarifying, classification, clinic, combine, conform, deferment, delisted, delisting, depreciation, derecognized, dilute, dispersion, electrical, employer, espionage, expired, Florida, foregoing, fourth, grace, hacker, harder, induction, interaction, Labour, letter, motive, Nasdaq, Orlando, practical, prevalent, realization, regain, regulated, relocated, repayable, repealed, requirement, residence, retrospective, rupturing, skin, substance